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Charaf BenarafaAbstract
Neutrophils are essential to combat infectious agents
but contribute to collateral inflammatory damage.
Likewise, neutrophils can kill cancer cells and have
been shown to promote malignant growth and
metastasis through immunosuppressive functions.
Two articles in a recent issue of Nature reveal new
mechanisms by which tumors induce changes in
neutrophil phenotype through production of
inflammatory cytokines. Although the two studies
report different outcomes on the effects of
neutrophils on tumor growth and metastasis, they
delineate novel molecular pathways influencing
neutrophil phenotype that may provide new
approaches to harnessing neutrophil functions in
the treatment of cancer.tumoral Met+ neutrophils was dependent on expressionNeutrophils develop in the bone marrow and rapidly
respond to danger signals by a prompt mobilization to
injured tissues, where they accumulate, amplify inflamma-
tory responses, eliminate pathogens, and sometimes
induce local tissue injury. Recent studies indicate that
neutrophils can acquire phenotypic changes with mark-
edly altered functions and increased survival [1]. In cancer
patients and tumor-bearing mice, a major question has
been the elusive origin and functional characterization of
tumor-associated neutrophils and granulocytic myeloid-
derived suppressor cells (G-MDSCs), which can be
considered a subset of neutrophils with immunosuppres-
sive activity on T cells. In two recent studies published in
Nature [2, 3], tumor-induced mechanisms were shown to
alter neutrophil numbers and function, highlighting the
plasticity of the neutrophil and its importance in control-
ling growth and invasiveness of cancer cells.Correspondence: charaf.benarafa@tki.unibe.ch
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tion of the tyrosine kinase receptor MET pathway. In
the first highlighted article, Finisguerra et al. investi-
gated the function of the MET proto-oncogene in stro-
mal cells, including leukocytes associated with tumors
[2]. They convincingly demonstrated that deletion of
MET in neutrophils was associated with increased
tumor growth and metastasis in multiple tumor models
in mice, including spontaneous mammary tumors
driven by transgenic expression of the polyoma virus
middle T (PyMT) antigen. Tumor necrosis factor-alpha
(TNF-α) and other soluble factors produced by tumor
cells were responsible for Met induction in a subset of
circulating neutrophils of tumor-bearing mice, and the
Met+ neutrophil subset was enriched within the tumor
mass and contributed to reduced tumor growth and
metastasis. Mechanistically, the transmigration of anti-
of high levels of hepatocyte growth factor (HGF), the
only ligand for MET, by the tumor. It remains unclear
why the transmigration of Met+ neutrophils in vivo was
dependent on HGF produced in the tumor environ-
ment when these neutrophils could potentially respond
to other chemotactic cues recruiting Met-negative neu-
trophils. Regardless, the investigators uncovered a po-
tential flaw in MET targeting therapy in cancer, where
the effects of MET kinase inhibitors, usually used to
block tumor growth, are dampened by the inhibition of
anti-tumoral neutrophils expressing Met.
Neutrophilia, or high neutrophil numbers in the cir-
culation, is a common observation in tumor-bearing
mice. Moreover, a high neutrophil-to-lymphocyte ratio
in patients with solid tumors is associated with poor
overall survival [4]. In the second highlighted article,
Coffelt et al. investigated the mechanisms leading to
the generation of large numbers of pro-metastatic im-
munosuppressive neutrophils in a single model of
breast cancer mediated by combined deletion of p53
and E-cadherin [3]. They found that tumor-induced
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that promotes granulopoiesis by inducing IL-17 and
granulocyte-colony-stimulating factor (G-CSF) [5].
Interestingly, depletion of immunosuppressive neutro-
phils and γδ T cells particularly impaired early meta-
static spread but had little effect on the primary
tumor growth. The pro-metastatic function of neutro-
phils was mediated by immunosuppression of CD8
cytotoxic T cells. Co-depletion of neutrophils and
CD8-positive cells reverted the anti-metastatic pheno-
type associated with neutrophil depletion. It will be
interesting to find out whether these findings are
reproduced in other models.
The two studies raise several issues about harnessing
inflammatory cytokines in cancer therapy. First, repur-
posing anti-inflammatory drugs and, more specifically,
antibodies blocking inflammatory cytokines that act
upstream of G-CSF could be envisaged for reducing
neutrophil production. Indeed, G-CSF was shown to
be necessary and sufficient to alter hematopoiesis in
favor of production of immunosuppressive neutrophils
in the PyMT model [6]. However, it is also likely that
tumor-induced inflammation concurrently promotes
the production of neutrophils with anti-tumor activity,
such as Met+ neutrophils. Therefore, the net effect of
such therapies may be variable depending on the
tumor type, the tissue, and the host response. Second,
concomitant inflammatory diseases and environmental
exposures, such as cigarette smoke, may affect breast
cancer growth and metastasis through effects on neu-
trophil phenotypes. Knowledge of molecular pathways
of neutrophil functions in cancer remains patchy. For
example, claims were made for the effects of inducible
nitric oxide synthase for both pro- and anti-tumoral
neutrophils in the two highlighted articles. This appar-
ent contradiction may be due to the fact that the same
neutrophil subset carries out both functions or that
neutrophil subsets need to be better defined depending
on the tumor and its microenvironment. Migratory
and localization profiles of neutrophils within the pri-
mary tumor, endothelial surfaces, and pre-metastatic
niches relative to tumor cells and T cells may tip the
balance in different directions. In vivo live cell imaging
of such interactions may be particularly revealing. In
conclusion, these studies show that tumor-associated
inflammation profoundly alters granulopoiesis and
simultaneously releases neutrophils with different mi-
gratory and anti-tumor properties. The defined path-
ways highlighted here provide the basis for further
studies to define intervention points to target tumor
type-specific neutrophil migration and function.
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